Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease

  • Kumarasinghe, L.
  • Ramirez, J.
  • Mayor, U.
  • Zugaza, J.L.
  • Sanz, P.
  • García-Gimeno, María Adelaida|||0000-0002-6483-3912
[EN] Laforin and Malin are two proteins that are encoded by the genes EPM2A and EPM2B, respectively. Laforin is a glucan phosphatase and Malin is an E3-ubiquitin ligase, and these two proteins function as a complex. Mutations occurring at the level of one of the two genes lead to the accumulation of an aberrant form of glycogen meant to cluster in polyglucosans that go under the name of Lafora bodies. Individuals affected by the appearance of these polyglucosans, especially at the cerebral level, experience progressive neurodegeneration and several episodes of epilepsy leading to the manifestation of a fatal form of a rare disease called Lafora disease (LD), for which, to date, no treatment is available. Despite the different dysfunctions described for this disease, many molecular aspects still demand elucidation. An effective way to unknot some of the nodes that prevent the achievement of better knowledge of LD is to focus on the substrates that are ubiquitinated by the E3-ubiquitin ligase Malin. Some substrates have already been provided by previous studies based on protein-protein interaction techniques and have been associated with some alterations that mark the disease. In this work, we have used an unbiased alternative approach based on the activity of Malin as an E3-ubiquitin ligase. We report the discovery of novel bonafide substrates of Malin and have characterized one of them more deeply, namely PIP3-dependent Rac exchanger 1 (P-Rex1). The analysis conducted upon this substrate sets the genesis of the delineation of a molecular pathway that leads to altered glucose uptake, which could be one of the origin of the accumulation of the polyglucosans present in the disease., This work has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement 813599 (TRIM-NET). We also want to acknowledge the support of the grant from the National Institutes of Health P01 NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), and a grant from la Fundacio La Marato TV3 (202032), to PS; and a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00 to PS and MGG.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease

  • Kumarasinghe, Lorena
  • García Gimeno, María Adelaida
  • Ramírez Sánchez, Juan Manuel
  • Mayor Martínez, Ugo
  • Zugaza Gurruchaga, José Luis
  • Sanz, Pascual
Laforin and Malin are two proteins that are encoded by the genes EPM2A and EPM2B, respectively. Laforin is a glucan phosphatase and Malin is an E3-ubiquitin ligase, and these two proteins function as a complex. Mutations occurring at the level of one of the two genes lead to the accumulation of an aberrant form of glycogen meant to cluster in polyglucosans that go under the name of Lafora bodies. Individuals affected by the appearance of these polyglucosans, especially at the cerebral level, experience progressive neurodegeneration and several episodes of epilepsy leading to the manifestation of a fatal form of a rare disease called Lafora disease (LD), for which, to date, no treatment is available. Despite the different dysfunctions described for this disease, many molecular aspects still demand elucidation. An effective way to unknot some of the nodes that prevent the achievement of better knowledge of LD is to focus on the substrates that are ubiquitinated by the E3-ubiquitin ligase Malin. Some substrates have already been provided by previous studies based on protein-protein interaction techniques and have been associated with some alterations that mark the disease. In this work, we have used an unbiased alternative approach based on the activity of Malin as an E3-ubiquitin ligase. We report the discovery of novel bonafide substrates of Malin and have characterized one of them more deeply, namely PIP3-dependent Rac exchanger 1 (P-Rex1). The analysis conducted upon this substrate sets the genesis of the delineation of a molecular pathway that leads to altered glucose uptake, which could be one of the origin of the accumulation of the polyglucosans present in the disease., We want to thank Dr. Atanasio Pandiella (CIC-Salamanca), Dr. Manuel Rodríguez (Proteomics Unit. CIC-bioGUNE. Bizkaia. Spain), and Dr. Ch. Blattner (Institute of Toxicology and Genetics. Karlsruhe Institute of Technology. Karlsruhe. Germany) for plasmids. We also thank the support provided by SGIker Proteomics service (UPV/EHU - ERDF. EU). This work has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement 813599 (TRIM-NET). We also want to acknowledge the support of the grant from the National Institutes of Health P01 NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), and a grant from la Fundació La Marató TV3 (202032), to PS; and a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00 to PS and MGG.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TRIM32 and Malin in Neurological and Neuromuscular Rare Diseases

  • Kumarasinghe, Lorena
  • Xiong, Lu
  • García-Gimeno, María Adelaida
  • Lazzari, Elisa
  • Sanz, Pascual
  • Meroni, Germana
21 páginas, 7 figuras. Some elements used in the figures were adapted from Servier Medical Art (https://smart.servier.com/) (accessed on 12 February 2021)., licensed under a Creative Commons Attribution 3.0 Generic License. Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cells10040820/s1, Table S1: Reported TRIM32 substrates/interactors listed alphabetically. Table S2: Reported malin substrates/interactors listed alphabetically, Tripartite motif (TRIM) proteins are RING E3 ubiquitin ligases defined by a shared domain structure. Several of them are implicated in rare genetic diseases, and mutations in TRIM32 and TRIM-like malin are associated with Limb-Girdle Muscular Dystrophy R8 and Lafora disease, respectively. These two proteins are evolutionary related, share a common ancestor, and both display NHL repeats at their C-terminus. Here, we revmniew the function of these two related E3 ubiquitin ligases discussing their intrinsic and possible common pathophysiological pathways., This work has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement 813599 (TRIM-NET). We also want to acknowledge the support of the grant from the National Institutes of Health P01 NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S. E.L. is supported by a post-doctoral grant issued by Fondazione Umberto Veronesi., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Identification of novel substrates of Malin E3 ubiquitin ligase in Lafora disease

  • Kumarasinghe, Lorena
  • García-Gimeno, María Adelaida
  • Ramírez, Juan Manuel
  • Mayor, Ugo
  • Sanz, Pascual
43rd Congress of the SEBBM Virtual, 19-22 de julio de 2021, Lafora disease (LD) is a progressive neurological disorder characterized by epileptic seizures, myoclonus, cerebellar symptoms and psychic deterioration. There is no cure and patients are treated in a palliative way with anti-epileptic drugs, towards which, after some time, they become re sistant. At the basis of the disease, there is a malfunction of two proteins, laforin and malin, encoded respectively by two genes: EPM2A and EPM2B. The two proteins form a complex and its incorrect functionality generates an error in the metabolism of glycogen leading to the accumulation of polyglucosan inclusions in patients. The polyglucosans, have an anomalous structure that prevents its normal deg radation leading to the formation of Lafora bodies. Studies conducted on brain samples of LD mouse models show a greater accumulation of polyglucosans at the level of astro cytes compared to neurons. Considering the role of malin, known to be an E3 ubiquitin ligase, involved the ubiquit ination of specific substrates, we performed a proteomic analysis of the enriched ubiquitinated fraction of proteins, in HEK293T cells expressing either wild type or an inactive form of malin carrying the pathogenic P69A mutation (the most prevalent mutation of EPM2B gene). In comparison to cells expressing the non-functional malin-P69A, a list of more ubiquitinated putative substrates in cells expressing wild type malin was obtained.The aim of this study is to validate these candidates as substrates of malin and then focus on the consequences of ubiquitination on their physiological function. This infor mation will allow the identification of putative therapeutic targets and develop new treatments that could ameliorate the pathology present in Lafora disease., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813599), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease

  • Kumarasinghe, Lorena
  • García-Gimeno, María Adelaida
  • Ramírez, J.
  • Mayor, U.
  • Zugaza, J. L.
  • Sanz, Pascual
14 páginas, 7 figuras, 1 tabla., Laforin and Malin are two proteins that are encoded by the genes EPM2A and EPM2B, respectively. Laforin is a glucan phosphatase and Malin is an E3-ubiquitin ligase, and these two proteins function as a complex. Mutations occurring at the level of one of the two genes lead to the accumulation of an aberrant form of glycogen meant to cluster in polyglucosans that go under the name of Lafora bodies. Individuals affected by the appearance of these polyglucosans, especially at the cerebral level, experience progressive neurodegeneration and several episodes of epilepsy leading to the manifestation of a fatal form of a rare disease called Lafora disease (LD), for which, to date, no treatment is available. Despite the different dysfunctions described for this disease, many molecular aspects still demand elucidation. An effective way to unknot some of the nodes that prevent the achievement of better knowledge of LD is to focus on the substrates that are ubiquitinated by the E3-ubiquitin ligase Malin. Some substrates have already been provided by previous studies based on protein-protein interaction techniques and have been associated with some alterations that mark the disease. In this work, we have used an unbiased alternative approach based on the activity of Malin as an E3-ubiquitin ligase. We report the discovery of novel bonafide substrates of Malin and have characterized one of them more deeply, namely PIP3-dependent Rac exchanger 1 (P-Rex1). The analysis conducted upon this substrate sets the genesis of the delineation of a molecular pathway that leads to altered glucose uptake, which could be one of the origin of the accumulation of the polyglucosans present in the disease., This work has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie SklodowskaCurie grant agreement 813599 (TRIM-NET). We also want to acknowledge the support of the grant from the National Institutes of Health P01 NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), and a grant from la Fundacio ´ La Marato ´ TV3 (202032), to PS; and a grant from the Spanish Ministry of Science and Innovation PID2020- 112972RB-I00 to PS and MGG., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Búsqueda y caracterización de sustratos fisiológicos de malina, la E3-ubiquitin ligasa implicada en la enfermedad de Lafora

  • Kumarasinghe, Lorena
Tesis doctoral, 123 páginas, en ingles y en español, [EN] Lafora disease (LD) is a rare genetic disease that mainly affects adolescents and belongs to the group of diseases known as Progressive Myoclonus Epilepsies (PMEs). It is a fatal form of progressive myoclonus epilepsy and has an incidence of less than 4 cases in a million people worldwide. LD is caused by the accumulation of aberrant glycogen-like inclusions known as Lafora bodies (LBs), which are present in several tissues but are predominantly found in the brain. These LBs are insoluble and their aggregation leads to cellular toxicity, generating several progressive neurological symptoms, including difficult-to-control seizures, myoclonus, ataxia, dementia, and other symptoms. There is currently no definitive cure for LD, and treatment is mainly symptomatic and supportive, focusing on controlling seizures and managing other symptoms as they arise. The disease is caused by mutations that fall onto genes that codify for two different proteins: Laforin and Malin. These proteins have different functions but work in complex with each other. My Ph.D. studies focused especially on Malin, known to be an E3 ubiquitin ligase which plays a major role in a process called ubiquitination. Therefore, Malin’s activity makes LD a disease connected to the ubiquitin system. Several substrates of Malin have been identified to date, including those involved in the accumulation of polyglucosans, impairment in the degradation processes at the level of the proteasome and autophagy, alteration of glutamatergic transmission and mitochondrial dysfunction. However, many molecular mechanisms leading to these conditions need further elucidation. The hunt for novel substrates could help to identify previously unidentified dysfunctions of Lafora disease and to gain a better understanding of the aforementioned pathophysiological alterations. A proteomic analysis using the bioUb strategy identified 88 differentially ubiquitinated potential candidates involved in protein folding, heat shock response, and regulation of mitochondrial function. Two proteins, P-Rex1 and Hsp90α, were chosen for further study due to their high ubiquitination rate and/or unique peptide number in the proteomic analysis. In this thesis, evidence will be reported in demonstrating how the first substrate is related to LD. We have validated the Malin-dependent ubiquitination of P-Rex1 and have focused on the effect of Malin on the function of P-Rex1 as a guanine-nucleotide exchange factor (GEF) in activating Rac1 GTPase and in increasing glucose uptake. The analysis conducted upon this substrate sets the genesis of the delineation of a molecular pathway that leads to altered glucose uptake, which could be one of the origins of the accumulation of the polyglucosans present in the disease. Experiments conducted for Hsp90α have validated it as a substrate of Malin, not only when it is overexpressed but also at endogenous level and, further on, we have hypothesized how it could possibly be related to the disease., [ES] La enfermedad de Lafora es una rara enfermedad genética que afecta principalmente a los adolescentes y pertenece al grupo de enfermedades conocidas como Epilepsias Mioclónicas Progresivas (PME). Es una forma fatal de epilepsia mioclónica progresiva y tiene una incidencia de menos de 4 casos en un millón de personas en todo el mundo. La LD es causada por la acumulación de inclusiones aberrantes similares al glucógeno conocidas como cuerpos de Lafora (LB), que están presentes en varios tejidos pero se encuentran predominantemente en el cerebro. Estos LB son insolubles y su agregación conduce a la toxicidad celular, generando varios síntomas neurológicos progresivos, que incluyen convulsiones de difícil control, mioclonías, ataxia, demencia y otros síntomas. Actualmente no existe una cura definitiva para la LD, y el tratamiento es principalmente sintomático y de apoyo, centrándose en controlar las convulsiones y manejar otros síntomas a medida que surgen. La enfermedad es causada por mutaciones en genes que codifican para dos proteínas diferentes: Laforin y Malin. Estas proteínas tienen diferentes funciones pero trabajan en forma compleja entre sí. Durante el doctorado, los estudios se centraron especialmente en Malina, conocida por ser una ubiquitina ligasa E3 que desempeña un papel importante en un proceso llamado ubiquitinación. Por lo tanto, la actividad de Malina convierte la enfermedad de Lafora en una enfermedad relacionada con el sistema de ubiquitinación. Se han identificado varios sustratos de Malina hasta ahora, incluidos los implicados en la acumulación de poliglucosanos, deterioro en los procesos de degradación a nivel del proteasoma y autofagia, alteración de la transmisión glutamatérgica y disfunción mitocondrial. Sin embargo, muchos mecanismos moleculares que conducen a estas condiciones necesitan mayor aclaración. La búsqueda de nuevos sustratos podría ayudar a identificar disfunciones de la enfermedad de Lafora no identificadas previamente y a una mayor comprensión de las alteraciones fisiopatológicas descritas anteriormente. Un análisis proteómico utilizando la estrategia bioUb identificó 88 candidatos potenciales diferencialmente ubiquitinados involucrados en el plegamiento de proteínas, la respuesta al choque térmico y la regulación de la función mitocondrial. Se eligieron dos proteínas, P-Rex1 y Hsp90α, para su posterior estudio debido a su alta tasa de ubiquitinación y número de péptido único en el análisis proteómico. En esta tesis, se reportarán evidencias para demostrar cómo el primer sustrato se relaciona con la enfermedad de Lafora. Se ha validado la ubiquitinación de P-Rex1 dependiente de Malina y hemos estudiado como esta modificación altera la actividad de P-Rex1 como factor intercambiador de nucleótidos de guanina (GEF) sobre la GTPasa Rac1 y en la toma de glucosa. El análisis realizado sobre este sustrato establece la génesis de una vía molecular que conduce a la alteración de la captación de glucosa, lo que podría ser uno de los orígenes de la acumulación de los poliglucosanos presentes en la enfermedad. Los experimentos realizados para Hsp90α la han validado como sustrato de Malina y, hemos hipotetizado cómo podría estar relacionada con la enfermedad., Este proyecto ha recibido financiación del Programa de Investigación e Innovación Horizonte 2020 de la Unión Europea bajo el acuerdo de subvención Marie Skłodowska-Curie No 813599, convocatoria H2020- MSCA-ITN-2018 - Innovative Training Networks 2018 del TRIM-NET A training network in drug discovery targeting TRIM ubiquitin ligases. También ha recibido financiación del proyecto PID2020-112972RB-I00 titulado “Estudio de la relación entre neuroinflamación y epilepsia: el caso de le enfermedad de Lafora”, del Programa RETOS del Ministerio de Ciencia e Innovación., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

USP24 is a cross-reactive DUB targeting MOV10 to regulate IFN-I production

  • Mukhopadhyay, Rishov
  • Draganov, Simeon D
  • Oosenbrug, Timo
  • Akkermans, Jimmy J L L
  • Kikkert, Marjolein
  • Knobeloch, Klaus-Peter
  • Fritz, Günter
  • Guzmán, María
  • Zúñiga Lucas, Sonia
  • Kim, Robbert Q
  • van der Veen, Annemarthe G
  • Kessler, Benedikt M
  • Pinto-Fernández, Adán
  • Geurink, Paul P
  • Sapmaz, Aysegul
The type I Interferon (IFN-I)-induced ubiquitin-like modifier Interferon-Stimulated Gene 15 (ISG15) plays a crucial role in the innate immune response against viral infections. ISG15 is conjugated to target proteins by an enzymatic cascade, called ISGylation. While ubiquitin-specific protease 18 (USP18) serves as the major deISGylase counteracting ISG15 conjugation, ISG15 cross-reactive deubiquitylating enzymes (DUBs) have also been reported. Here, we identify USP24 as an ISG15 cross-reactive DUB through activity-based protein profiling. USP24 processes pro-ISG15 and ISG15-linked substrates in vitro, and its depletion increases ISG15 conjugates following interferon stimulation in cells without altering canonical IFN-I signaling. USP24 knockout cells show increased IFN-β and ISG expression upon activation of cytosolic RNA sensing via viral mimicry. Proteomic analysis identifies RNA helicase Moloney leukemia virus 10 (MOV10) as a specific target of USP24 for deISGylation. Our data revealed that ISGylation of MOV10 promotes MOV10 interaction with IFIT3 and enhances IFN-β production/secretion in response to viral stimuli. This process is negatively regulated by USP24, which directly deISGylates MOV10. Our data highlight USP24's role in modulating ISGylation and IFN-I production, suggesting USP24 as a potential therapeutic agent for infectious and inflammatory diseases., This work was supported by the TRIM-NET project, which received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813599. A.S was supported by ICI00026 from the NWO Gravity Program. S.D., A.P.F., and B.M.K. were supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China [grant number: 2018-I2M-2-002] and by Pfizer. Work in the A.P.F. lab was funded by Ono Pharma UK Ltd. S.Z. was supported by the Government of Spain (PID2022-140328OB-I00, MCIN/AEI/10.13039/501100011033/FEDER, UE). M.G. received a contract from Comunidad de Madrid (PIPF-2022/SAL-GL-24549). K.P.K. received funding from the German Research Foundation (DFG), Project ID DFG 423813989/GRK2606, and under Germany’s Excellence Strategy (CIBSS–EXC-2189–Project ID 390939984). T.O. and A.G.V.D.V. were supported by a research grant from the Institute for Chemical Immunology (ICI-00203 and ICI-00046), which is funded by a Gravitation project (024.002.009) from the Dutch Research Council (NWO), a VIDI research grant (09150171910070), and an Aspasia award (015.015.046) from the NWO, and the LUMC., Peer reviewed